These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35939775)

  • 1. Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study.
    Riva E; Duarte PJ; Valcárcel B; Remaggi G; Murrieta I; Corzo A; Del Carpio D; Peña C; Vásquez J; Bove V; Teixeira L; Fleury-Perini G; Yantorno S; Samánez C; Lopresti S; Altamirano M; Villela L; Ruiz-Arguelles GJ; Ruiz-Delgado GJ; Montaño E; Verri V; Zamora Pérez E; Pérez Jacobo F; Idrobo H; Martínez-Cordero H; Beltran BE; Ramírez J; Castillo JJ; Malpica Castillo LE
    JCO Glob Oncol; 2022 Aug; 8():e2100380. PubMed ID: 35939775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients].
    Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092
    [No Abstract]   [Full Text] [Related]  

  • 3. Bortezomib-based chemotherapy for patients with Waldenström macroglobulinemia: a single-center experience.
    Liu Z; Jiang S; Gu J; Liu H; Song G; Cao X
    Ann Hematol; 2023 Jan; 102(1):167-174. PubMed ID: 36374339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical characteristics and prognosis of patients with Waldenström macroglobulinemia and its comparison with the Pivotal study].
    Tao Y; Wang S; Wang L; Wu M; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):993-997. PubMed ID: 35045669
    [No Abstract]   [Full Text] [Related]  

  • 5. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
    Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
    Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First Latin America report on the diagnostic utility of the study of the MYD88 L265P gene mutation in patients with Waldenström Macroglobulinemia.
    Giuliani F; Pavlovsky MA; Giere I; Fernandez I; Sackmann F; Pavlovsky A; Remaggi G; Castillo JJ
    Ann Hematol; 2022 Oct; 101(10):2365-2367. PubMed ID: 35794278
    [No Abstract]   [Full Text] [Related]  

  • 8. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
    Abeykoon JP; Paludo J; King RL; Ansell SM; Gertz MA; LaPlant BR; Halvorson AE; Gonsalves WI; Dingli D; Fang H; Rajkumar SV; Lacy MQ; He R; Kourelis T; Reeder CB; Novak AJ; McPhail ED; Viswanatha DS; Witzig TE; Go RS; Habermann TM; Buadi FK; Dispenzieri A; Leung N; Lin Y; Thompson CA; Hayman SR; Kyle RA; Kumar SK; Kapoor P
    Am J Hematol; 2018 Feb; 93(2):187-194. PubMed ID: 29080258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
    Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
    Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
    [No Abstract]   [Full Text] [Related]  

  • 11. Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.
    Guidez S; Labreuche J; Drumez E; Ysebaert L; Bakala J; Delette C; Hivert B; Protin C; Declercq H; Verlay M; Marolleau JP; Duhamel A; Morel P;
    Blood Adv; 2018 Nov; 2(22):3102-3111. PubMed ID: 30455359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical characteristics and prognosis of Waldenström's macroglobulinemia: a clinical data report from a single center].
    Jia YC; Lu J; Qiang WT; Li L; Liu J; Jiang H; Fu WJ; Du J
    Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1020-1024. PubMed ID: 33445850
    [No Abstract]   [Full Text] [Related]  

  • 13. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
    Kapoor P; Paludo J; Ansell SM
    Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating low CD4
    Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
    Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of the MYD88
    Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX
    Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and biological characteristics of non-IgM lymphoplasmacytic lymphoma].
    Yu Y; Xiong WJ; Chen JW; Jiao Y; Yan YT; Wang Q; Zou DH; Liu W; Liu HM; Lyu R; Qiu LG; Yi SH
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):568-574. PubMed ID: 36709134
    [No Abstract]   [Full Text] [Related]  

  • 17. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
    Treon SP; Gustine J; Meid K; Yang G; Xu L; Liu X; Demos M; Kofides A; Tsakmaklis N; Chen JG; Munshi M; Chan G; Dubeau T; Raje N; Yee A; O'Donnell E; Hunter ZR; Castillo JJ
    J Clin Oncol; 2018 Sep; 36(27):2755-2761. PubMed ID: 30044692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
    Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
    Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYD88 L265P mutation in Waldenstrom macroglobulinemia.
    Poulain S; Roumier C; Decambron A; Renneville A; Herbaux C; Bertrand E; Tricot S; Daudignon A; Galiègue-Zouitina S; Soenen V; Theisen O; Grardel N; Nibourel O; Roche-Lestienne C; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
    Blood; 2013 May; 121(22):4504-11. PubMed ID: 23532735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.